Provided by Tiger Trade Technology Pte. Ltd.

Pfizer

25.90
-0.0500-0.19%
Post-market: 25.900.0005+0.00%19:59 EDT
Volume:22.32M
Turnover:578.82M
Market Cap:147.26B
PE:19.73
High:26.15
Open:26.00
Low:25.76
Close:25.95
52wk High:28.75
52wk Low:22.88
Shares:5.69B
Float Shares:5.68B
Volume Ratio:0.66
T/O Rate:0.39%
Dividend:1.72
Dividend Rate:6.64%
EPS(TTM):1.31
EPS(LYR):1.36
ROE:8.31%
ROA:5.69%
PB:1.63
PE(LYR):18.98

Loading ...

Pfizer Juggles Trial Win, Setback and New Vaccine Bet

TIPRANKS
·
Yesterday

Market View -- Barrons.com

Dow Jones
·
Yesterday

Pfizer’s Bevacizumab Biosimilar Study in Japan: What Investors Should Watch

TIPRANKS
·
Yesterday

Pfizer Advances New Migraine Tablet Formulation With Phase 1 Bioequivalence Study

TIPRANKS
·
Yesterday

Pfizer’s Phase 3 Lyme Vaccine Trial Nears the Finish Line: What Investors Should Know

TIPRANKS
·
Yesterday

Pfizer Terminates Early KRAS Cancer Trial: What It Means for PFE Investors

TIPRANKS
·
Yesterday

Pfizer China and MediTrust Health Forge Strategic Alliance

Deep News
·
May 21

Moderately bullish activity in Pfizer with shares up 0.41%

TIPRANKS
·
May 21

FACTBOX-Pharma sector doubles down on AI amid hopes of slashing costs, timelines

Reuters
·
May 20

Sarah Cannon Research Institute: Announces Strategic Oncology Research Collaboration With Pfizer

THOMSON REUTERS
·
May 20

Pfizer Says Next-Generation Pneumococcal Vaccine Showed Stronger Immune Response in Infant Study

MT Newswires Live
·
May 20

Pfizer announces pneumococcal conjugate vaccine candidate data

TIPRANKS
·
May 20

Pfizer: Initiated Its Phase 3 25Vpnc Pediatric Program

THOMSON REUTERS
·
May 20

Pfizer: About 9 to 15-Fold Higher Serotype 3 Immunogenicity Response After Dose 3 & 4 in Infants Receiving 25Vpnc VS Prevnar 20

THOMSON REUTERS
·
May 20

Pfizer: 25Vpnc Phase 2 Data Shows Robust Immunogenicity, Including Enhanced Response Against Serotype 3, With Expanded Protection Across 25 Serotypes

THOMSON REUTERS
·
May 20

Pfizer: Adult Pneumococcal Vaccine Candidate Expected to Enter Clinical Development by End of 2026

THOMSON REUTERS
·
May 20

Pfizer: Advances Pivotal Pediatric Pneumococcal Vaccine Program Following Strong Positive Phase 2 Results

THOMSON REUTERS
·
May 20

Pfizer: 25Vpnc Well-Tolerated With No Safety Concerns Identified in Phase 2 Study

THOMSON REUTERS
·
May 20

Pfizer: 25Vpnc Expected to Cover up to 90% of Disease-Causing Serotypes in Children Under Age of 5, Including About 15% From Serotype 3

THOMSON REUTERS
·
May 20

Pfizer Keeps Oncology Upside As Rigel Takes VEPPANU PROTAC Lead

Simply Wall St.
·
May 20